Aptevo's Mipletamig Triplet Achieves 93% Clinical Benefit in TP53-Mutated AML
APVO sits 28% above its 52-week low of $1.37 on elevated volume (16× avg).
Summary
Aptevo reported a 93% clinical benefit rate for its lead candidate mipletamig in combination with venetoclax and azacitidine in frontline TP53-mutated AML. The 79% complete remission rate nearly doubles the 41% published for the venetoclax/azacitidine backbone alone. This is the first disclosure of these efficacy numbers from the RAINIER trial, a Phase 1b/2 study in newly diagnosed AML patients unfit for intensive chemotherapy. The company expects to complete dose optimization by year-end and hold regulatory meetings in H1 2027. The data strengthens the case for mipletamig in a high-risk population with few effective options, though the small sample size (14 evaluable patients) warrants caution. The stock was down 22% at publication, suggesting the market may have expected even stronger results or is focused on the company's going concern risk and recent dilutive financing.
At the time of this announcement, APVO was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $1.37 to $48.78. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.